UBS Group
FULC icon

UBS Group’s Fulcrum Therapeutics FULC Stock Holding History

UBS Group’s Portfolio FULC Stock Details FULC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.42M Buy
315,185
+212,218
+206% +$1.97M ﹤0.01% 4802
2025
Q4 		$1.16M Sell
102,967
-198,190
-66% -$2.02M ﹤0.01% 5440
2025
Q3 		$2.77M Buy
301,157
+165,952
+123% +$1.2M ﹤0.01% 4655
2025
Q2 		$930K Buy
135,205
+63,285
+88% +$339K ﹤0.01% 5506
2025
Q1 		$207K Sell
71,920
-5,472
-7% -$20.1K ﹤0.01% 6539
2024
Q4 		$364K Sell
77,392
-3,241
-4% -$12K ﹤0.01% 6063
2024
Q3 		$288K Sell
80,633
-109,918
-58% -$815K ﹤0.01% 5600
2024
Q2 		$1.18M Buy
190,551
+117,783
+162% +$892K ﹤0.01% 4254
2024
Q1 		$687K Buy
72,768
+42,585
+141% +$380K ﹤0.01% 4930
2023
Q4 		$204K Buy
30,183
+19,026
+171% +$84.4K ﹤0.01% 5771
2023
Q3 		$49.5K Sell
11,157
-20,602
-65% -$90K ﹤0.01% 6294
2023
Q2 		$105K Buy
31,759
+31,335
+7,390% +$92.1K ﹤0.01% 5980
2023
Q1 		$1.21K Sell
424
-3,365
-89% -$30.1K ﹤0.01% 8780
2022
Q4 		$27.6K Buy
+3,789
New +$24.7K ﹤0.01% 7327
2022
Q2 		– Sell
-1,469
Closed -$35K – 10529
2022
Q1 		$35K Buy
1,469
+644
+78% +$9.12K ﹤0.01% 6845
2021
Q4 		$15K Sell
825
-480
-37% -$9.51K ﹤0.01% 8244
2021
Q3 		$37K Buy
1,305
+363
+39% +$6.88K ﹤0.01% 6567
2021
Q2 		$10K Sell
942
-579
-38% -$5.85K ﹤0.01% 8038
2021
Q1 		$18K Buy
1,521
+1,191
+361% +$14.7K ﹤0.01% 7460
2020
Q4 		$4K Sell
330
-2,896
-90% -$32.7K ﹤0.01% 7908
2020
Q3 		$26K Sell
3,226
-1,114
-26% -$13.4K ﹤0.01% 6095
2020
Q2 		$79K Sell
4,340
-3,773
-47% -$59.4K ﹤0.01% 5491
2020
Q1 		$97K Buy
8,113
+2,006
+33% +$32.1K ﹤0.01% 5319
2019
Q4 		$101K Buy
6,107
+1,664
+37% +$15.9K ﹤0.01% 6003
2019
Q3 		$29K Buy
+4,443
New +$49.2K ﹤0.01% 6507

Other funds holding FULC

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
FTM
First Turn Management Del Mar, California $895M AUM 261.28% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return

UBS Group's FULC Position: Q1 2026 in Review

UBS Group increased its Fulcrum Therapeutics (FULC) stake by 206% in Q1 2026, buying an estimated $1.97M and bringing the position to 315,185 shares worth $2.42M. The position accounts for ﹤0.01% of the portfolio, ranked #4802.

UBS Group first reported a position in FULC in Q3 2019 and has held it in 25 quarters since. The position peaked at $2.77M in Q3 2025. 169 funds tracked by Wall St. Rank hold FULC as of Q1 2026.

  • UBS Group held 315,185 shares of Fulcrum Therapeutics worth $2.42M as of Q1 2026.
  • UBS Group bought 212,218 Fulcrum Therapeutics shares in Q1 2026, an estimated $1.97M.
  • Fulcrum Therapeutics made up ﹤0.01% of UBS Group's portfolio in Q1 2026, its #4802 holding.
  • UBS Group first reported a position in Fulcrum Therapeutics in Q3 2019 and has held it in 25 quarters since.
  • UBS Group's Fulcrum Therapeutics position peaked at $2.77M in Q3 2025.
  • 169 funds tracked by Wall St. Rank held Fulcrum Therapeutics as of Q1 2026.

Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.